Hard times for oncogenic BRAF-expressing melanoma cells.

@article{Houslay2011HardTF,
  title={Hard times for oncogenic BRAF-expressing melanoma cells.},
  author={Miles D Houslay},
  journal={Cancer cell},
  year={2011},
  volume={19 1},
  pages={
          3-4
        }
}
In this issue of Cancer Cell, Arozarena et al. describe that the oncogenic BRAF Val600Glu mutant, which occurs in about half of melanomas, downregulates the cGMP-hydrolysing phosphodiesterase PDE5A in melanoma cells through the ERK-MAPK cascade coupled to the POU-domain transcription factor BRN2, thereby increasing intracellular cGMP levels and promoting invasiveness. 
BETA

Figures and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

ADMET considerations for phosphodiesterase-5 inhibitors.

  • Expert opinion on drug metabolism & toxicology
  • 2012
VIEW 1 EXCERPT
CITES BACKGROUND

Similar Papers